Novartis First Quarter Sales Bolstered By Gleevec, Diovan
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmaceutical revenues are up 6 percent, hampered by a 19 percent drop in U.S. pharma sales.
You may also be interested in...
No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus
Novartis is joining the horde of pharmaceutical companies that are revamping their sales and marketing organizations in response to a U.S. market that is rapidly changing, at varying paces in different regions
No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus
Novartis is joining the horde of pharmaceutical companies that are revamping their sales and marketing organizations in response to a U.S. market that is rapidly changing, at varying paces in different regions
Novartis To Acquire Majority Stake In Alcon
Deal offers synergies with firm’s Ciba Vision affiliate and ex-U.S. marketing rights to Lucentis.